Buy or sell Bolt Biotherapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

View More Companies

Bolt Biotherapeutics Stock

Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.

About Bolt Biotherapeutics Stock

Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.

Funding History

March 2015$600K
September 2016$10.0M
August 2018$19.4M
February 2019$54.0M

Management

President and CEO

Reiner Laus

Chief Business Officer

Grant Yonehiro

Chief Executive Officer and Director

CP Liu

Founder

Edgar Engleman

Other Companies

Brickell Biotech Logo
Learn More
Learn More
Brickell Biotech
Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.
$25.4MTotal Funding
Jounce Therapeutics Logo
Learn More
Learn More
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
$103MTotal Funding
PanTheryx Logo
Learn More
Learn More
PanTheryx
Intestinal health research, development, and commercialization products
$77.3MTotal Funding
Rani Therapeutics Logo
Learn More
Learn More
Rani Therapeutics
Rani Therapeutics develops bio-therapeutics technology for the oral delivery of large drug molecules.
$143MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Bolt Biotherapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo